Biomarkers for gastrointestinal adverse events related to thiopurine therapy
| Autor: | Gabriele Stocco, Raffaella Franca, Giulia Zudeh, Giuliana Decorti |
|---|---|
| Přispěvatelé: | Zudeh, G., Franca, R., Stocco, G., Decorti, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Lymphoblastic Leukemia PACSIN2 Gastrointestinal toxicity Gastrointestinal adverse effects ITPA Immunologic Factor Internal medicine Azathioprine medicine Humans Immunologic Factors Pyrophosphatases Adverse effect Methyltransferase Thiopurines Thiopurine methyltransferase biology Thiopurine business.industry Mercaptopurine Biomarkers RAC1 Methyltransferases Gastroenterology Gastrointestinal adverse effect Inflammatory Bowel Diseases General Medicine Biomarker Discontinuation Editorial biology.protein business Human |
| Zdroj: | World Journal of Gastroenterology |
| Popis: | Thiopurines are immunomodulators used in the treatment of acute lymphoblastic leukemia and inflammatory bowel diseases. Adverse reactions to these agents are one of the main causes of treatment discontinuation or interruption. Myelosuppression is the most frequent adverse effect; however, approximately 5%-20% of patients develop gastrointestinal toxicity. The identification of biomarkers able to prevent and/or monitor these adverse reactions would be useful for clinicians for the proactive management of long-term thiopurine therapy. In this editorial, we discuss evidence supporting the use of PACSIN2, RAC1, and ITPA genes, in addition to TPMT and NUDT15, as possible biomarkers for thiopurine-related gastrointestinal toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|